{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:36:34Z","timestamp":1791218194612,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.lpm.2017.01.015","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T09:00:54Z","timestamp":1488877254000},"page":"e13-e21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"P2","title":["Tuberculosis elimination and the challenge of latent tuberculosis"],"prefix":"10.1016","volume":"46","author":[{"given":"Alberto","family":"Matteelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Sulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haileyesus","family":"Getahun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2017.01.015_bib0365","series-title":"Global tuberculosis report\u00a02016","first-page":"1","author":"World Health Organization","year":"2016"},{"issue":"7","key":"10.1016\/j.lpm.2017.01.015_bib0370","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.lpm.2017.01.015_bib0375","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.lpm.2017.01.015_bib0380","doi-asserted-by":"crossref","first-page":"S1179","DOI":"10.1093\/infdis\/jir451","article-title":"Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response","volume":"204","author":"Achkar","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.015_bib0385","doi-asserted-by":"crossref","first-page":"e02537","DOI":"10.1128\/mBio.02537-14","article-title":"Characterization of host and microbial determinants in individuals with latent tuberculosis infection using a human granuloma model","volume":"6","author":"Guirado","year":"2015","journal-title":"mBio"},{"issue":"22","key":"10.1016\/j.lpm.2017.01.015_bib0390","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"issue":"9979","key":"10.1016\/j.lpm.2017.01.015_bib0395","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO's new END-TB strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.lpm.2017.01.015_bib0400","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1056\/NEJMp1510082","article-title":"Shifting to Sustainable Development Goals \u2013 implications for global health","volume":"373","author":"Murray","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2017.01.015_bib0405","series-title":"Guidelines on the management of latent tuberculosis infection","first-page":"1","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.lpm.2017.01.015_bib0410","series-title":"Implementing the END-TB Strategy: the essentials","first-page":"1","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.lpm.2017.01.015_bib0415","series-title":"Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings","first-page":"1","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.lpm.2017.01.015_bib0420","series-title":"Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries","first-page":"1","author":"World Health Organization","year":"2012"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.015_bib0425","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1183\/09031936.00205512","article-title":"Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination","volume":"42","author":"Diel","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.015_bib0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3402\/gha.v7.23695","article-title":"The Millennium Development Goals: experiences, achievements and what's next","volume":"7","author":"Lomazzi","year":"2014","journal-title":"Global Health Action"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.015_bib0435","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1183\/13993003.00449-2016","article-title":"Advancing global programmatic management of latent tuberculosis infection for at risk populations","volume":"47","author":"Getahun","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.015_bib0440","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries","volume":"45","author":"Lonnroth","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.015_bib0445","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1183\/09031936.00198813","article-title":"Tuberculosis elimination: theory and practice in Europe","volume":"43","author":"D\u2019Ambrosio","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.015_bib0450","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2214-109X(13)70032-9","article-title":"Domestic and donor financing for tuberculosis care and control in low-income and middle-income countries: an analysis of trends, 2002\u201311, and requirements to meet\u00a02015 targets","volume":"1","author":"Floyd","year":"2013","journal-title":"Lancet Glob Health"},{"issue":"Suppl. 3","key":"10.1016\/j.lpm.2017.01.015_bib0455","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/civ608","article-title":"Translating the Tuberculosis Research Agenda: much accomplished, but much more to be done","volume":"61","author":"Schito","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.015_bib0460","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/S1473-3099(16)00070-0","article-title":"Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers","volume":"16","author":"Wallis","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.015_bib0465","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/trstmh\/trw016","article-title":"TB vaccine development and the END-TB Strategy: importance and current status","volume":"110","author":"Fletcher","year":"2016","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.015_bib0470","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence","volume":"99","author":"Comstock","year":"1974","journal-title":"Am J Epidemiol"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.015_bib0475","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.015_bib0480","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/BOR.0b013e3283025ec2","article-title":"Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies","volume":"20","author":"Keane","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.015_bib0485","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/TP.0000000000000133","article-title":"Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period","volume":"98","author":"Sidhu","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.lpm.2017.01.015_bib0490","first-page":"231","article-title":"Infections caused by Mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation","volume":"4","author":"Al-Anazi","year":"2014","journal-title":"Front Oncol"},{"issue":"17","key":"10.1016\/j.lpm.2017.01.015_bib0495","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1097\/00002030-200012010-00016","article-title":"HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners","volume":"14","author":"Corbett","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.lpm.2017.01.015_bib0500","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2369-10-36","article-title":"Risk factors for tuberculosis in dialysis patients: a prospective multi-center clinical trial","volume":"10","author":"Christopoulos","year":"2009","journal-title":"BMC Nephrol"},{"issue":"12","key":"10.1016\/j.lpm.2017.01.015_bib0505","doi-asserted-by":"crossref","first-page":"e1000381","DOI":"10.1371\/journal.pmed.1000381","article-title":"Tuberculosis incidence in prisons: a systematic review","volume":"7","author":"Baussano","year":"2010","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.lpm.2017.01.015_bib0510","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.1989.03420090053030","article-title":"Prospective study of human immunodeficiency virus infection and pregnancy outcomes in intravenous drug users","volume":"261","author":"Selwyn","year":"1989","journal-title":"JAMA"},{"issue":"2 Pt. 1","key":"10.1016\/j.lpm.2017.01.015_bib0515","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1164\/ajrccm.162.2.9910055","article-title":"Tuberculosis in the homeless. A prospective study","volume":"162","author":"Moss","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.015_bib0520","doi-asserted-by":"crossref","first-page":"e38556","DOI":"10.1371\/journal.pone.0038556","article-title":"Factors associated with the performance of a blood-based interferon-gamma release assay in diagnosing tuberculosis","volume":"7","author":"Banfield","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.015_bib0525","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1111\/j.1532-5415.2011.03367.x","article-title":"Use of interferon-gamma release assay for latent tuberculosis infection screening in older adults exposed to tuberculosis in a nursing home","volume":"59","author":"Katsenos","year":"2011","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.015_bib0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.201302-0365OC","article-title":"Interferon-gamma release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States","volume":"189","author":"Dorman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.015_bib0535","doi-asserted-by":"crossref","first-page":"e1000391","DOI":"10.1371\/journal.pmed.1000391","article-title":"Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies","volume":"8","author":"Getahun","year":"2011","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.015_bib0540","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1183\/09031936.00070812","article-title":"Contact investigation for tuberculosis: a systematic review and meta-analysis","volume":"41","author":"Fox","year":"2013","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.015_bib0545","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1183\/13993003.01245-2015","article-title":"Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries","volume":"46","author":"Getahun","year":"2015","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.lpm.2017.01.015_bib0550","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.5588\/ijtld.16.0241","article-title":"Policies and practices on the programmatic management of latent tuberculous infection: global survey","volume":"20","author":"Hamada","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.015_bib0555","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1128\/CMR.00034-13","article-title":"Gamma interferon release assays for detection of Mycobacterium tuberculosis infection","volume":"27","author":"Pai","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.lpm.2017.01.015_bib0560","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in tuberculosis","volume":"31","author":"O\u2019Garra","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.lpm.2017.01.015_bib0565","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(00)02742-2","article-title":"Specific immune based diagnosis of tuberculosis","volume":"356","author":"Andersen","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.015_bib0570","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1183\/09031936.00115110","article-title":"Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis","volume":"37","author":"Diel","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2017.01.015_bib0575","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2017.01.015_bib0580","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lpm.2017.01.015_bib0585","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","article-title":"Systematic review: T\u00a0cell-based assays for the diagnosis of latent tuberculosis infection: an update","volume":"149","author":"Pai","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2017.01.015_bib0590","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14737159.6.3.413","article-title":"New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis","volume":"6","author":"Pai","year":"2006","journal-title":"Expert Rev Mol Diagn"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.015_bib0595","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1378\/chest.11-3157","article-title":"Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis","volume":"142","author":"Diel","year":"2012","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.lpm.2017.01.015_bib0600","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(11)70210-9","article-title":"Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis","volume":"12","author":"Rangaka","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.015_bib0605","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/thoraxjnl-2011-200956","article-title":"Single-step QuantiFERON screening of adult contacts: a prospective cohort study of tuberculosis risk","volume":"68","author":"Haldar","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.lpm.2017.01.015_bib0610","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1164\/rccm.201201-0026OC","article-title":"Identifying predictors of interferon-gamma release assay results in pediatric latent tuberculosis: a protective role of bacillus Calmette\u2013Guerin? A pTB-NET collaborative study","volume":"186","author":"Basu Roy","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.015_bib0615","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1002\/eji.201243262","article-title":"Mycobacterium tuberculosis-specific CD8+ T\u00a0cells are functionally and phenotypically different between latent infection and active disease","volume":"43","author":"Rozot","year":"2013","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.015_bib0620","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.diagmicrobio.2012.11.023","article-title":"Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection","volume":"75","author":"Nikolova","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.015_bib0625","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jinf.2014.06.009","article-title":"Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients","volume":"69","author":"Chiacchio","year":"2014","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.lpm.2017.01.015_bib0630","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1164\/rccm.201107-1355OC","article-title":"CD8+ T\u00a0cells provide an immunologic signature of tuberculosis in young children","volume":"185","author":"Lancioni","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.015_bib0635","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1183\/13993003.00510-2016","article-title":"First evaluation of QuantiFERON-TB Gold Plus performance in contact screening","volume":"48","author":"Barcellini","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.015_bib0640","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1183\/13993003.01464-2015","article-title":"Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection","volume":"47","author":"Hoff","year":"2016","journal-title":"Eur Respir J"},{"issue":"10035","key":"10.1016\/j.lpm.2017.01.015_bib0645","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/S0140-6736(15)01316-1","article-title":"A blood RNA signature for tuberculosis disease risk: a prospective cohort study","volume":"387","author":"Zak","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2017.01.015_bib0650","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1086\/444463","article-title":"National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection","volume":"41","author":"McElroy","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.lpm.2017.01.015_bib0655","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection \u2013 a network meta-analysis","volume":"161","author":"Stagg","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.lpm.2017.01.015_bib0660","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Counterpoint","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"10.1016\/j.lpm.2017.01.015_bib0665","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1128\/AAC.00554-08","article-title":"Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations","volume":"52","author":"Dooley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.lpm.2017.01.015_bib0670","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1128\/AAC.45.12.3631-3634.2001","article-title":"Postantibiotic effects of antituberculosis agents alone and in combination","volume":"45","author":"Chan","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.lpm.2017.01.015_bib0675","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.43.5.1230","article-title":"Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a Phase\u00a0I study","volume":"43","author":"Keung","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"10.1016\/j.lpm.2017.01.015_bib0680","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2017.01.015_bib0685","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.lpm.2017.01.015_bib0690","series-title":"Adherence to once-weekly self-administered INH and rifapentine for latent TB: iAdhere. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, 23\u201326\u00a0February\u00a02015","author":"Belknap","year":"2015"},{"key":"10.1016\/j.lpm.2017.01.015_bib0695","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.lpm.2017.01.015_bib0700","author":"Sanofi-Aventis US"},{"key":"10.1016\/j.lpm.2017.01.015_bib0705","unstructured":"Department of Health and Human Services (DHHS). Panel on Antiretroviral Guidelines for Adults, Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf [Last access: December\u00a018,\u00a02016]."},{"issue":"e-1","key":"10.1016\/j.lpm.2017.01.015_bib0710","first-page":"233","article-title":"Rifapentine once-weekly dosing effect on efavirenz, emtricitabine and tenofovir PKs. Conference on Retroviruses and Opportunistic Infections, March 3\u20136; Boston, MA","volume":"22","author":"Farenc","year":"2014","journal-title":"Top Antivir Med"},{"issue":"8","key":"10.1016\/j.lpm.2017.01.015_bib0715","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.lpm.2017.01.015_bib0720","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkt483","article-title":"Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers","volume":"69","author":"Weiner","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498217300556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498217300556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T10:57:47Z","timestamp":1658746667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498217300556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0755498217300556"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.015","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tuberculosis elimination and the challenge of latent tuberculosis","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.016","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2017.01.017","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}